Checkpoint inhibitors offer significant improvements in cancer care, yet even in combination with other checkpoint inhibitors or monoclonal antibodies, their results remain unsatisfactory for many. As Daniel Teper, CEO of Cytovia Therapeutics pointed out, “The best standard of care for advanced hepatocellular carcinoma (HCC) – a combination of atezolizumab (anti-PDL1 antibody) and bevacizumab (anti-VEGF antibody) – offers less […]

Cancer therapies are, increasingly, throwing one-two punches at cancer. For example, Sutro Biopharma presented Phase I data at the American Association for Cancer Research (AACR) Annual Meeting on April 8 showing that its lead compound, STRO-002, not only kills the tumor but also elicits immunogenic cell death. “STRO-002 is in phase I trials for ovarian and endometrial cancer. It’s a […]

New data from the open-label extension trial of the phase 2 RESCUE-ALS study (NCT04098406) for amyotrophic lateral sclerosis (ALS) suggest nanocrystalline gold (CNM-Au8; Clene Nanomedicine, Salt Lake City, UT) slows clinical decline. RESCUE-ALS is a phase 2 study that is not powered for statistical analysis of survival. Using the European Network for the Cure of […]